From Promise to Proof: What Science Really Says About Ivermectin and Mebendazole in Cancer Treatment

Table of Contents:

1. Introduction: From Curiosity to Clinical Relevance
2. Why Repurposed Drugs Matter in Cancer Research
3. The Science Behind Ivermectin and Mebendazole
4. Courage Against Cancer’s Ovarian Cancer Preclinical Study
5. What Evidence Shows So Far
6. The Challenges Ahead
7. Why Your Support Matters
8. How to Help: Donate or Shop the Healing Store

---

Introduction: From Curiosity to Clinical Relevance

Across the world, researchers are revisiting familiar drugs in new ways. Once known only for fighting parasites, ivermectin and mebendazole are now at the forefront of an emerging movement in oncology — drug repurposing.

At Courage Against Cancer (CAC), Coco believes that innovation often begins by asking brave questions others avoid. Our foundation has taken a significant step forward by initiating a preclinical trial proposal studying ivermectin and mebendazole as potential treatments for ovarian cancer — a disease urgently in need of new therapeutic strategies.

---

Why Repurposed Drugs Matter in Cancer Research

Repurposing drugs offers a unique advantage: decades of safety data already exist. This means new anti-cancer applications can move more rapidly from the lab to patient trials, saving both time and cost.

For patients facing aggressive or treatment-resistant cancers, these therapies represent hope rooted in scientific logic — not speculation.

---

The Science Behind Ivermectin and Mebendazole

Ivermectin

Originally developed as an antiparasitic, ivermectin has demonstrated anti-tumor, anti-inflammatory, and immune-modulating effects in multiple preclinical studies. It appears to disrupt cancer cell metabolism, inhibit angiogenesis (tumor blood vessel growth), and induce apoptosis (programmed cell death).

Mebendazole / Fenbendazole

Best known as a deworming medication, mebendazole / fenbendazole interferes with microtubule formation, the scaffolding that allows cancer cells to divide and spread. Studies have shown its ability to suppress tumor growth and reduce metastasis in models of lung, thyroid, and brain cancers.

---

Courage Against Cancer’s Ovarian Cancer Preclinical Study

CAC’s newly initiated preclinical trial proposal is focused on testing the combined and individual effects of ivermectin and mebendazole against ovarian cancer cells. This research aims to answer key scientific questions:

• Do these compounds selectively target ovarian cancer cells without harming healthy tissue?
• What are the most effective dosage combinations and timing?
• Could these drugs enhance the response to existing chemotherapy agents?

The project will begin at the preclinical stage, which means it will first evaluate the cellular and molecular effects in laboratory and animal models — a critical first step toward FDA approval and human clinical trials.

This effort represents a milestone for CAC: translating our mission from advocacy into active scientific contribution.

---

What Evidence Shows So Far

Recent publications have demonstrated compelling data:

• Ivermectin suppresses the Wnt/β-catenin and YAP1 pathways — both of which are implicated in tumor proliferation and drug resistance.
• Mebendazole (Fenbendazole) reduces tumor angiogenesis and interferes with key signaling proteins essential for cancer growth.
• Combined, these agents have shown additive and sometimes synergistic effects in preclinical cancer models.

While early findings are promising, it’s essential to note that human trials are still limited. That’s exactly why Courage Against Cancer’s preclinical work is so vital — to generate the rigorous, peer-reviewed data required to move these therapies forward responsibly.

---

The Challenges Ahead

Repurposed drugs face uphill battles in research funding and regulatory approval. Because they are off-patent and inexpensive, large pharmaceutical companies have little incentive to invest in their development.

As a nonprofit, CAC exists to fill that gap — ensuring that potentially life-saving treatments aren’t overlooked simply because they don’t promise billion-dollar profits.

---

Why Your Support Matters

Every donation and product purchase helps fuel real cancer research — not just talk. CAC’s team of scientists, physicians, and advocates are working tirelessly to prove what many patients already believe: that healing is possible when courage meets science.

Your support directly funds studies like our ovarian cancer trial proposal and helps amplify awareness of safe, effective, affordable alternatives.

---

How to Help: Donate or Shop the Healing Store

You can be part of this movement today.
Visit our Healing Store — where every purchase directly supports our mission to fund innovative, non-traditional cancer research. From educational guides to immune-support supplements, your contribution makes a tangible difference.

Every day, thousands of families face cancer with limited options — but your generosity can change that. By donating to Courage Against Cancer (CAC), you help fund real scientific research into non-traditional, affordable, and repurposed cancer therapies like ivermectin and mebendazole. Our mission is to bring hope and healing where conventional systems have fallen short — by advancing evidence-based, natural, and alternative therapies toward FDA-recognized validation.

Every contribution, large or small, directly supports our ongoing preclinical study on ovarian cancer, educational outreach, and future clinical trial development.
✨ Join us in transforming courage into cures.

---

Disclaimer: Courage Against Cancer provides scientific information for educational purposes only. This is not medical advice. The proposed clinical trial is in the planning stages and is not yet recruiting patients. All treatment decisions must be made in consultation with a qualified healthcare provider.